论文部分内容阅读
目的 : 观察新型药物白三烯受体拮抗剂安可来对哮喘的防治作用及其不良反应。方法 : 6 3例轻、中度哮喘患者随机分为安可来组 38例 ,40mg/d ;曲尼斯特组 2 7例 ,30 0mg/d。共服用 6周。 结果 : 安可来组服药前后第 1秒用力呼气量 (FEV1.0 )由 (1.79± 0 .5 1)升至 (1.94± 0 .6 6 ) ,升幅 8.4% ;曲尼司特组由 (1.5 5± 0 .6 5 )升至 (1.6 5± 0 .83) ,升幅 6 .5 % ;安可来组 %FEV1.0升幅达 9.2 % ,明显高于曲尼司特组 3.3% (P <0 .0 5 ) ;安可来组在夜间憋醒次数与肺部体征方面明显少于曲尼司特组 ,但无显著差异 ;安可来组有 1例患者ALT轻度升高 ,停药 2周后降至正常 ;临床综合评价 ,安可来组有效率为 74.4% ,明显高于曲尼司特组 (5 6 .5 % )。结论 :安可来是一种治疗轻、中度哮喘的有效药物 ,患者有良好的依从性 ,肺功能改善明显 ,且不良反应少。
Objective: To observe the prevention and treatment of asthma and its adverse reactions by a novel drug leukotriene receptor antagonist. Methods: Sixty-three patients with mild to moderate asthma were randomly divided into three groups: ancrodine group (38 cases), 40 mg / day, and transthrema group (27 cases). Take a total of 6 weeks. Results: In forced-acting group, forced expiratory volume (FEV1.0) increased from (1.79 ± 0.51) to (1.94 ± 0.66) (1.5 5 ± 0.65) to (1.6 5 ± 0.83), an increase of 6.5%. In the amphetamines group, the% FEV1.0 increased by 9.2%, significantly higher than that in the tranilast group (3.3% P <0.05). The incidence of atrial appearding was significantly lower in patients in the alkaline group than in the tranilast group at night, but no significant difference was found between the two groups. One patient in the aloe group had a slight increase in ALT, After 2 weeks of withdrawal, the patients were reduced to normal. Clinical comprehensive evaluation showed that the effective rate of Amracil group was 74.4%, significantly higher than Tranilast group (56.5%). Conclusions: Encrodine is an effective drug for the treatment of mild to moderate asthma. The patients have good compliance, obvious improvement of pulmonary function, and few adverse reactions.